PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
暂无分享,去创建一个
V. Jinga | Andra-Elena Balcangiu-Stroescu | M. Greabu | D. Miricescu | Silviu Badoiu | Iulia-Ioana Stănescu-Spînu | Constantin Ștefani | D. Mihai | Radu Ilinca | I. Vacaroiu | D. Balan | I. A. Vacaroiu | S. Badoiu
[1] M. Maggi,et al. Radiogenomics in Renal Cancer Management—Current Evidence and Future Prospects , 2023, International journal of molecular sciences.
[2] Hao Huang,et al. A novel lipid metabolism gene signature for clear cell renal cell carcinoma using integrated bioinformatics analysis , 2023, Frontiers in Cell and Developmental Biology.
[3] O. Andronic,et al. Oral Arginine Supplementation in Healthy Individuals Performing Regular Resistance Training , 2023, Healthcare.
[4] L. Spain,et al. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature , 2023, Current oncology.
[5] Mohammad H Al-thnaibat,et al. Etiologies, Gross Appearance, Histopathological Patterns, Prognosis, and Best Treatments for Subtypes of Renal Carcinoma: An Educational Review , 2022, Cureus.
[6] Guo Ci Teo,et al. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness. , 2022, Cancer cell.
[7] Mark W. Ball,et al. Tumorigenesis Mechanisms Found in Hereditary Renal Cell Carcinoma: A Review , 2022, Genes.
[8] R. Bardan,et al. Contemporary Clinical Definitions, Differential Diagnosis, and Novel Predictive Tools for Renal Cell Carcinoma , 2022, Biomedicines.
[9] J. Carles,et al. Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease , 2022, Frontiers in Oncology.
[10] N. Khurana,et al. Primary leiomyosarcoma kidney – A rare entity with a diagnostic challenge , 2022, Journal of cancer research and therapeutics.
[11] D. Sahu,et al. Differential expression profiling of onco and tumor-suppressor genes from major-signaling pathways in Wilms’ tumor , 2022, Pediatric Surgery International.
[12] W. Kaelin. Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer , 2022, The Journal of clinical investigation.
[13] Tao Lin,et al. Immune-related gene signature associates with immune landscape and predicts prognosis accurately in patients with Wilms tumour , 2022, Frontiers in Immunology.
[14] M. Tretiakova. What’s new in kidney tumor pathology 2022: WHO 5th edition updates , 2022, Journal of pathology and translational medicine.
[15] Yang Liu,et al. A Randomized Study on the Effect of Metformin Combined with Intensive-Exercise Diet Therapy on Glucose and Lipid Metabolism and Islet Function in Patients with Renal Cell Carcinoma and Diabetes , 2022, Disease markers.
[16] R. Wilson,et al. Molecular Heterogeneity in Pediatric Malignant Rhabdoid Tumors in Patients With Multi-Organ Involvement , 2022, Frontiers in Oncology.
[17] M. Rubin,et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2022, European urology.
[18] A. Hong,et al. Recent Advances in Renal Medullary Carcinoma , 2022, International journal of molecular sciences.
[19] N. Ahmed,et al. Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma , 2022, Frontiers in Medicine.
[20] Jinu Kim,et al. Mitochondrial metabolic reprogramming by SIRT3 regulation ameliorates drug resistance in renal cell carcinoma , 2022, PloS one.
[21] Ming Wu,et al. C1q/tumour necrosis factor-related protein-3 alleviates high-glucose-induced lipid accumulation and necroinflammation in renal tubular cells by activating the adenosine monophosphate-activated protein kinase pathway. , 2022, The international journal of biochemistry & cell biology.
[22] U. Hofmann,et al. Nicotinamide‐N‐methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma , 2022, Clinical and translational medicine.
[23] R. Mehrazin,et al. Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions , 2022, Cancers.
[24] H. Chang,et al. Identification of HGD and GSTZ1 as Biomarkers Involved Metabolic Reprogramming in Kidney Renal Clear Cell Carcinoma , 2022, International journal of molecular sciences.
[25] M. Chintagumpala,et al. Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534) , 2022, Cancer.
[26] S. Daneshmand,et al. Pediatric genitourinary tumors: Distribution, demographics, and outcomes , 2022, Pediatric investigation.
[27] T. Darré,et al. Renal Leiomyosarcoma, a Rare Presentation , 2022, Journal of kidney cancer and VHL.
[28] M. Baranowski,et al. Grade‐dependent changes in sphingolipid metabolism in clear cell renal cell carcinoma , 2022, Journal of cellular biochemistry.
[29] H. Al-Ali,et al. Adaptive and maladaptive roles of lipid droplets in health and disease. , 2022, American journal of physiology. Cell physiology.
[30] Xinjian Li,et al. Fumarate inhibits PTEN to promote tumorigenesis and therapeutic resistance of type2 papillary renal cell carcinoma. , 2022, Molecular cell.
[31] Teruhiko Yoshida,et al. A novel pathogenic variant of the FH gene in a family with hereditary leiomyomatosis and renal cell carcinoma , 2022, Human Genome Variation.
[32] Shivani Akula,et al. The role of mediator subunit 12 in tumorigenesis and cancer therapeutics , 2022, Oncology letters.
[33] Erguang Li,et al. Single-cell chromatin accessibility landscape in kidney identifies additional cell-of-origin in heterogenous papillary renal cell carcinoma , 2022, Nature Communications.
[34] Yunwei Han,et al. Biological Role and Mechanism of Lipid Metabolism Reprogramming Related Gene ECHS1 in Cancer , 2022, Technology in cancer research & treatment.
[35] Wei Yan,et al. FOXF2 Regulates PRUNE2 Transcription in the Pathogenesis of Colorectal Cancer , 2022, Technology in cancer research & treatment.
[36] Xudong Yang,et al. Role of Metabolic Reprogramming of Long non-coding RNA in Clear Cell Renal Cell Carcinoma , 2022, Journal of Cancer.
[37] R. Mehra,et al. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates , 2021, Asian journal of urology.
[38] N. Nonomura,et al. Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a narrative review , 2021, Translational andrology and urology.
[39] H. Daw,et al. Overview of histologic variants of urothelial carcinoma: current trends and narrative review on treatment outcomes , 2021, Translational andrology and urology.
[40] T. Deguchi,et al. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential VHL Mutations Underlie Multifocal ccRCC , 2022, Cancer Genomics & Proteomics.
[41] Beata Franczyk,et al. Characteristics of Clear Cell Papillary Renal Cell Carcinoma (ccpRCC) , 2021, International journal of molecular sciences.
[42] P. Russo,et al. Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome , 2021, Modern Pathology.
[43] A. Italiano,et al. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review , 2021, Frontiers in Immunology.
[44] Yidong Fan,et al. SETD8 stabilized by USP17 epigenetically activates SREBP1 pathway to drive lipogenesis and oncogenesis of ccRCC. , 2021, Cancer letters.
[45] Kui-Sheng Chen,et al. Targeting PI3K/Akt signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.
[46] Degang Ding,et al. Revealing potential lipid biomarkers in clear cell renal cell carcinoma using targeted quantitative lipidomics , 2021, Lipids in health and disease.
[47] L. Matherly,et al. Lipid metabolism reprogramming in renal cell carcinoma , 2021, Cancer and Metastasis Reviews.
[48] E. Henske,et al. Renal Cell Carcinoma in Tuberous Sclerosis Complex , 2021, Genes.
[49] Guangzhen Wu,et al. The Uniqueness of Clear Cell Renal Cell Carcinoma: Summary of the Process and Abnormality of Glucose Metabolism and Lipid Metabolism in ccRCC , 2021, Frontiers in Oncology.
[50] Laurentiu M. Pop,et al. Renal Lipid Metabolism Abnormalities in Obesity and Clear Cell Renal Cell Carcinoma , 2021, Metabolites.
[51] Fengzhi Li,et al. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma , 2021, Journal of experimental & clinical cancer research : CR.
[52] Yan Lin,et al. Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis , 2021, Theranostics.
[53] M. Weber,et al. Primary renal sarcomas: imaging features and discrimination from non-sarcoma renal tumors , 2021, European Radiology.
[54] C. Rübe,et al. Prognostic Factors for Wilms Tumor Recurrence: A Review of the Literature , 2021, Cancers.
[55] Hui Zheng,et al. VHL regulates the sensitivity of clear cell renal cell carcinoma to SIRT4-mediated metabolic stress via HIF-1α/HO-1 pathway , 2021, Cell Death & Disease.
[56] Sounak Gupta. An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique. , 2021, Urologic oncology.
[57] S. Pal,et al. "Collecting duct carcinoma of the kidney: diagnosis and implications for management". , 2021, Urologic oncology.
[58] S. Yuan,et al. Targeting GLS1 to cancer therapy through glutamine metabolism , 2021, Clinical and Translational Oncology.
[59] T. Choueiri,et al. Metabolic reprogramming in renal cancer: Events of a metabolic disease. , 2021, Biochimica et biophysica acta. Reviews on cancer.
[60] M. Björkholm,et al. Regulatory region mutations of TERT, PLEKHS1 and GPR126 genes as urinary biomarkers in upper tract urothelial carcinomas , 2021, Journal of Cancer.
[61] F. Baltazar,et al. Cancer Cells’ Metabolism Dynamics in Renal Cell Carcinoma Patients’ Outcome: Influence of GLUT-1-Related hsa-miR-144 and hsa-miR-186 , 2021, Cancers.
[62] R. Garje,et al. Comprehensive Review of Chromophobe Renal Cell Carcinoma. , 2021, Critical reviews in oncology/hematology.
[63] L. Pellerin,et al. Inhibition of eIF5A hypusination reprogrammes metabolism and glucose handling in mouse kidney , 2021, Cell Death & Disease.
[64] M. Simon,et al. Glycogen metabolism is dispensable for tumor progression in clear cell renal cell carcinoma , 2021, Nature Metabolism.
[65] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[66] G. Sauter,et al. Y-chromosome loss is frequent in male renal tumors , 2021, Annals of translational medicine.
[67] Nora C. Toussaint,et al. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. , 2021, Cancer cell.
[68] M. Gessler,et al. Characteristics and outcome of pediatric renal cell carcinoma patients registered in the International Society of Pediatric Oncology (SIOP) 93‐01, 2001 and UK‐IMPORT database: A report of the SIOP‐Renal Tumor Study Group , 2021, International journal of cancer.
[69] M. V. Heiden,et al. Cell Programmed Nutrient Partitioning in the Tumor Microenvironment , 2020, bioRxiv.
[70] J. Mora,et al. Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations , 2020, Cancers.
[71] C. Porta,et al. Integration of Lipidomics and Transcriptomics Reveals Reprogramming of the Lipid Metabolism and Composition in Clear Cell Renal Cell Carcinoma , 2020, Metabolites.
[72] M. Yaspo,et al. Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma , 2020, Cancer Research.
[73] Jong-il Kim,et al. Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data , 2020, Annals of translational medicine.
[74] W. Kaelin,et al. Targeting the HIF2–VEGF axis in renal cell carcinoma , 2020, Nature Medicine.
[75] Yifan Chen,et al. Research progress of mTOR inhibitors. , 2020, European journal of medicinal chemistry.
[76] G. Lopes,et al. Unusual Presentation of Renal Medullary Carcinoma With Undiagnosed Sickle Cell Trait , 2020, Cureus.
[77] J. Hsieh,et al. Targeting Metabolic Pathways in Kidney Cancer , 2020, Cancer journal.
[78] F. Tang,et al. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy , 2020, Journal of cellular physiology.
[79] U. Testa,et al. Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets , 2020, Medicines.
[80] G. De Velasco,et al. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome , 2020, Modern Pathology.
[81] E. Philip,et al. Genomic profiling in renal cell carcinoma , 2020, Nature Reviews Nephrology.
[82] A. Papavassiliou,et al. Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma. , 2020, Cancer letters.
[83] W. Rathmell,et al. Beyond glycolysis: Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma. , 2020, Cancer letters.
[84] A. Kallam,et al. Clear Cell Renal Carcinoma , 2020 .
[85] Tao Tao,et al. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges , 2020, Cell & Bioscience.
[86] Christian M. Metallo,et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer , 2020, Nature Cell Biology.
[87] James R. Anderson,et al. Activity of Vincristine and Irinotecan in Diffuse Anaplastic Wilms Tumor and Therapy Outcomes of Stage II to IV Disease: Results of the Children's Oncology Group AREN0321 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] F. Baltazar,et al. The metabolic landscape of urological cancers: new therapeutic perspectives. , 2020, Cancer letters.
[89] L. Cantley,et al. Insulin–PI3K signalling: an evolutionarily insulated metabolic driver of cancer , 2020, Nature Reviews Endocrinology.
[90] Hiromi I. Wettersten,et al. Reprogramming of Metabolism in Kidney Cancer. , 2020, Seminars in nephrology.
[91] C. Creighton. Proteomic signatures of clear cell renal cell carcinoma , 2019, Nature Reviews Nephrology.
[92] M. Broggini,et al. Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth , 2019, Journal of Experimental & Clinical Cancer Research.
[93] Marcello Polesel,et al. Targeting Glycolysis in Proliferative Kidney Diseases. , 2019, American journal of physiology. Renal physiology.
[94] Bing Su,et al. Sin1-mediated mTOR signaling in cell growth, metabolism and immune response , 2019, National science review.
[95] Sungpil Yoon,et al. Knockdown of Pyruvate Kinase M2 Inhibits Cell Proliferation, Metabolism, and Migration in Renal Cell Carcinoma , 2019, International journal of molecular sciences.
[96] Guo Ci Teo,et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma , 2019, Cell.
[97] Fatima Shirly Anitha,et al. Atypical Presentation of Renal Leiomyosarcoma: A Case Report , 2019, Cureus.
[98] Yi Xiao,et al. Glutathione Metabolism in Renal Cell Carcinoma Progression and Implications for Therapies , 2019, International Journal of Molecular Sciences.
[99] Xianrang Song,et al. Physiological functions of Wilms’ tumor 1‐associating protein and its role in tumourigenesis , 2019, Journal of cellular biochemistry.
[100] A. Carnero,et al. c‐MYB‐ and PGC1a‐dependent metabolic switch induced by MYBBP1A loss in renal cancer , 2019, Molecular oncology.
[101] J. Katzenellenbogen,et al. Free Fatty Acids Rewire Cancer Metabolism in Obesity-Associated Breast Cancer via Estrogen Receptor and mTOR Signaling. , 2019, Cancer research.
[102] R. Henrique,et al. The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma , 2019, Genes.
[103] Scott R. Kennedy,et al. Abnormal oxidative metabolism in a quiet genomic background underlies clear cell papillary renal cell carcinoma , 2019, eLife.
[104] Y. Akao,et al. Synthetic miR-143 Exhibited an Anti-Cancer Effect via the Downregulation of K-RAS Networks of Renal Cell Cancer Cells In Vitro and In Vivo , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.
[105] E. Bruner,et al. Renal Medullary Carcinoma. , 2019, Archives of pathology & laboratory medicine.
[106] T. A. Al Hussain,et al. Papillary Renal Cell Carcinoma (PRCC): An Update. , 2019, Advances in anatomic pathology.
[107] P. Dzięgiel,et al. The Usefulness of Immunohistochemistry in the Differential Diagnosis of Lesions Originating from the Myometrium , 2019, International journal of molecular sciences.
[108] Gemma Sangüesa,et al. mTOR is a Key Protein Involved in the Metabolic Effects of Simple Sugars , 2019, International journal of molecular sciences.
[109] W. Linehan,et al. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. , 2019, Clinical genitourinary cancer.
[110] A. Fan,et al. The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy , 2019, Kidney cancer.
[111] Yuquan Wei,et al. Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization , 2019, Cell Death & Disease.
[112] W. Rathmell,et al. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers , 2019, The Journal of clinical investigation.
[113] A. Nukui,et al. Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications , 2019, International braz j urol : official journal of the Brazilian Society of Urology.
[114] D. Barupal,et al. Arginine reprogramming in ADPKD results in arginine-dependent cystogenesis. , 2018, American journal of physiology. Renal physiology.
[115] C. Greenwood,et al. Translational and HIF-1α-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. , 2018, Cell metabolism.
[116] N. Agarwal,et al. Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities , 2018, Research and reports in urology.
[117] Y. Takuwa,et al. The class II phosphoinositide 3-kinases PI3K-C2α and PI3K-C2β differentially regulate clathrin-dependent pinocytosis in human vascular endothelial cells , 2018, The Journal of Physiological Sciences.
[118] D. Smiraglia,et al. Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy , 2018, Clinical Cancer Research.
[119] E. Paraskeva,et al. Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia. , 2018, Biochimica et biophysica acta. Molecular and cell biology of lipids.
[120] M. Simon,et al. Genetic and metabolic hallmarks of clear cell renal cell carcinoma. , 2018, Biochimica et biophysica acta. Reviews on cancer.
[121] V. Haucke,et al. Autoregulation of Class II Alpha PI3K Activity by Its Lipid-Binding PX-C2 Domain Module. , 2018, Molecular cell.
[122] G. Medina-Gómez,et al. Maintenance of Kidney Metabolic Homeostasis by PPAR Gamma , 2018, International journal of molecular sciences.
[123] D. Felsher,et al. The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma , 2018, Oncogene.
[124] Yu Cheng,et al. PTEN in kidney cancer: A review and meta-analysis. , 2018, Clinica chimica acta; international journal of clinical chemistry.
[125] Y. T. Yeung,et al. Signaling Pathways in Inflammation and Anti-inflammatory Therapies. , 2018, Current pharmaceutical design.
[126] E. Lam,et al. Renal cell carcinoma: a review of biology and pathophysiology , 2018, F1000Research.
[127] R. Weiss. Metabolomics and Metabolic Reprogramming in Kidney Cancer. , 2018, Seminars in nephrology.
[128] A. Hartmann,et al. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin. , 2018, European urology focus.
[129] Hao Yang,et al. SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-κB signaling. , 2018, Biochemical and biophysical research communications.
[130] Ping Zhang,et al. The pro-apoptosis effect of sinomenine in renal carcinoma via inducing autophagy through inactivating PI3K/AKT/mTOR pathway. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[131] E. Burdmann,et al. Assessment of Kidney Function in Patients With Cancer. , 2018, Advances in chronic kidney disease.
[132] B. Delahunt,et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading , 2017, Histopathology.
[133] S. Welford,et al. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism , 2017, Nature Communications.
[134] H. Nishiyama,et al. Epidemiology of urothelial carcinoma , 2017, International journal of urology : official journal of the Japanese Urological Association.
[135] Ligong Chen,et al. Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity , 2017, Archives of Toxicology.
[136] Lewis C. Cantley,et al. The PI3K Pathway in Human Disease , 2017, Cell.
[137] B. Caldwell,et al. Current Management for Pediatric Urologic Oncology. , 2017, Advances in pediatrics.
[138] L. Elo,et al. HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma , 2017, Cancer & metabolism.
[139] Emanuel J. V. Gonçalves,et al. Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells , 2017, bioRxiv.
[140] R. Weiss,et al. Metabolic reprogramming in clear cell renal cell carcinoma , 2017, Nature Reviews Nephrology.
[141] Xiaoqiang Guo,et al. The Emerging Role of Histone Demethylases in Renal Cell Carcinoma , 2017, Journal of kidney cancer and VHL.
[142] G. Stephanopoulos,et al. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers , 2017, The Journal of clinical investigation.
[143] Y. Oda,et al. Oncogenic roles of SMARCB1/INI1 and its deficient tumors , 2017, Cancer science.
[144] Charles Swanton,et al. Renal cell carcinoma , 2017, Nature Reviews Disease Primers.
[145] E. Grande,et al. Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy. , 2017, Critical reviews in oncology/hematology.
[146] M. Aoki,et al. Oncogenic Roles of the PI3K/AKT/mTOR Axis. , 2017, Current topics in microbiology and immunology.
[147] U. Tateishi,et al. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy , 2017, BMC Cancer.
[148] N. Schultz,et al. Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets , 2016, Nature Communications.
[149] K. Gardner,et al. Targeting renal cell carcinoma with a HIF-2 antagonist , 2016, Nature.
[150] J. Backer. The intricate regulation and complex functions of the Class III phosphoinositide 3-kinase Vps34. , 2016, The Biochemical journal.
[151] H. Verheul,et al. Novel drugs that target the metabolic reprogramming in renal cell cancer , 2016, Cancer & Metabolism.
[152] M. Schipma,et al. PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell Carcinoma , 2016, PloS one.
[153] H. Moch,et al. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. , 2016, European urology.
[154] Chris Sander,et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. , 2016, Cell reports.
[155] R. Piñeiro,et al. Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression , 2016, Oncotarget.
[156] D. Hsu,et al. Cystine Deprivation Triggers Programmed Necrosis in VHL-Deficient Renal Cell Carcinomas. , 2016, Cancer research.
[157] Alessandro Conti,et al. Metabolic Alterations in Renal and Prostate Cancer. , 2016, Current drug metabolism.
[158] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.
[159] C. Arteaga,et al. The PI3K/AKT Pathway as a Target for Cancer Treatment. , 2016, Annual review of medicine.
[160] J. Fish,et al. Lanzkowsky's Manual of Pediatric Hematology and Oncology , 2016 .
[161] Liping Han,et al. Prognostic significance of two lipid metabolism enzymes, HADHA and ACAT2, in clear cell renal cell carcinoma , 2016, Tumor Biology.
[162] Xuejun Jiang,et al. Akt inhibition attenuates rasfonin-induced autophagy and apoptosis through the glycolytic pathway in renal cancer cells , 2015, Cell Death and Disease.
[163] R. Montironi,et al. Metabolic alterations in renal cell carcinoma. , 2015, Cancer treatment reviews.
[164] K. Pritchard-Jones,et al. Advances in Wilms Tumor Treatment and Biology: Progress Through International Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[165] C. Kieda,et al. The Role of Hypoxia and Cancer Stem Cells in Renal Cell Carcinoma Pathogenesis , 2015, Stem Cell Reviews and Reports.
[166] W. Sperl,et al. Energy metabolism in neuroblastoma and Wilms tumor. , 2015, Translational pediatrics.
[167] R. Cetin-Atalay,et al. The PI3K/AKT/mTOR interactive pathway. , 2015, Molecular bioSystems.
[168] P. Hawkins,et al. PI3K signalling in inflammation. , 2015, Biochimica et biophysica acta.
[169] V. Muglia,et al. Renal cell carcinoma: histological classification and correlation with imaging findings* , 2015, Radiologia brasileira.
[170] D. Ribatti,et al. Metabolomic profile of glycolysis and the pentose phosphate pathway identifies the central role of glucose-6-phosphate dehydrogenase in clear cell-renal cell carcinoma , 2015, Oncotarget.
[171] P. Oefner,et al. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism , 2015, Oncotarget.
[172] H. Öztürk. Prognostic features of renal sarcomas (Review) , 2014, Oncology letters.
[173] W. Rathmell,et al. Renal cell carcinoma , 2014, BMJ : British Medical Journal.
[174] F. Kawakami,et al. Clear cell papillary renal cell carcinoma: a review. , 2014, International journal of clinical and experimental pathology.
[175] R. Nussbaum,et al. Renal Cell Carcinoma in Tuberous Sclerosis Complex , 2014, The American journal of surgical pathology.
[176] Yingying Wang,et al. GRP78 enhances the glutamine metabolism to support cell survival from glucose deficiency by modulating the β-catenin signaling , 2014, Oncotarget.
[177] U. Völker,et al. Kidney protein profiling of Wilms' tumor patients by analysis of formalin-fixed paraffin-embedded tissue samples. , 2014, Clinica chimica acta; international journal of clinical chemistry.
[178] Jiri Polivka,et al. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. , 2014, Pharmacology & therapeutics.
[179] B. Ku,et al. Increased expression of transglutaminase 2 drives glycolytic metabolism in renal carcinoma cells , 2014, Amino Acids.
[180] R. Sun,et al. Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. , 2014, Cell metabolism.
[181] C. Rommel,et al. PI3K and cancer: lessons, challenges and opportunities , 2014, Nature Reviews Drug Discovery.
[182] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[183] D. Mukhopadhyay,et al. Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer , 2013, Molecular Cancer Therapeutics.
[184] C. Betz,et al. Where is mTOR and what is it doing there? , 2013, The Journal of cell biology.
[185] F. Marchi,et al. Genomic Signatures Predict Poor Outcome in Undifferentiated Pleomorphic Sarcomas and Leiomyosarcomas , 2013, PloS one.
[186] W. Linehan,et al. Aerobic glycolysis: a novel target in kidney cancer , 2013, Expert review of anticancer therapy.
[187] W Marston Linehan,et al. Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer , 2013, Clinical Cancer Research.
[188] E. Hirsch,et al. Targeting PI3K in Cancer: Any Good News? , 2013, Front. Oncol..
[189] W. Linehan,et al. Renal Medullary Carcinoma: Molecular, Immunohistochemistry, and Morphologic Correlation , 2013, The American journal of surgical pathology.
[190] G. Stephanopoulos,et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.
[191] H. Axelson,et al. Kidney cancer. , 2013, Seminars in cancer biology.
[192] F. Khuri,et al. Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation. , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[193] Jing Pan,et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. , 2012, Carcinogenesis.
[194] V. Haase,et al. Renal cancer: oxygen meets metabolism. , 2012, Experimental cell research.
[195] R. Stanton. Glucose‐6‐phosphate dehydrogenase, NADPH, and cell survival , 2012, IUBMB life.
[196] B. Hemmings,et al. PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis , 2012, Expert Reviews in Molecular Medicine.
[197] W. Marston Linehan,et al. Reductive carboxylation supports growth in tumor cells with defective mitochondria , 2011, Nature.
[198] J. Montani,et al. PI3Kγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance , 2011, Proceedings of the National Academy of Sciences.
[199] M. Rosenblum,et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel–Lindau gene and hypoxia-inducible factor pathway-related proteins , 2011, Modern Pathology.
[200] E. Jacinto,et al. mTOR complex 2 signaling and functions , 2011, Cell cycle.
[201] V. Huff,et al. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene , 2011, Nature Reviews Cancer.
[202] F. Kim,et al. Molecular aspects of renal cell carcinoma: a review. , 2011, American journal of cancer research.
[203] J. Tabernero,et al. Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.
[204] M. van Engeland,et al. VHL and HIF signalling in renal cell carcinogenesis , 2010, The Journal of pathology.
[205] W. Linehan,et al. The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.
[206] M. Adamo,et al. Current Perspectives on Akt Akt-ivation and Akt-ions , 2009, Experimental biology and medicine.
[207] D. Sabatini,et al. mTOR signaling at a glance , 2009, Journal of Cell Science.
[208] W. Krek,et al. Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. , 2009, Cell metabolism.
[209] W. Linehan,et al. Targeting the Met signaling pathway in renal cancer , 2009, Expert review of anticancer therapy.
[210] N. Sebire,et al. Paediatric renal tumours: recent developments, new entities and pathological features , 2009, Histopathology.
[211] M. Hall,et al. mTOR-what does it do? , 2008, Transplantation proceedings.
[212] J. McKiernan,et al. Epidemiology, clinical staging, and presentation of renal cell carcinoma. , 2008, The Urologic clinics of North America.
[213] J. Frank,et al. Absence of fumarate hydratase mutation in a family with cutaneous leiomyosarcoma and renal cancer , 2008, International journal of dermatology.
[214] V. Huff,et al. Wilms tumor genetics: Mutations in WT1, WTX, and CTNNB1 account for only about one‐third of tumors , 2008, Genes, chromosomes & cancer.
[215] P. Vogt,et al. Oncogenic signaling of class I PI3K isoforms , 2008, Oncogene.
[216] P. Hawkins,et al. PI3K Class IB Pathway , 2007, Science's STKE.
[217] C. Kolbitsch,et al. PTEN expression in renal cell carcinoma and oncocytoma and prognosis , 2007, Pathology.
[218] C. Godinot,et al. Mitochondria and reactive oxygen species in renal cancer. , 2007, Biochimie.
[219] W. Linehan,et al. Pseudohypoxic Pathways in Renal Cell Carcinoma , 2007, Clinical Cancer Research.
[220] C. Godinot,et al. Actuality of Warburg’s views in our understanding of renal cancer metabolism , 2007, Journal of bioenergetics and biomembranes.
[221] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[222] W. Linehan,et al. HIF and fumarate hydratase in renal cancer , 2007, British Journal of Cancer.
[223] P. Hawkins,et al. Signalling through Class I PI3Ks in mammalian cells. , 2006, Biochemical Society transactions.
[224] N. Breslow,et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[225] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[226] J. Blenis,et al. mTOR Controls Cell Cycle Progression through Its Cell Growth Effectors S6K1 and 4E-BP1/Eukaryotic Translation Initiation Factor 4E , 2004, Molecular and Cellular Biology.
[227] L. Cantley,et al. Rheb fills a GAP between TSC and TOR. , 2003, Trends in biochemical sciences.
[228] H. Tabuchi,et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor , 2003, Oncogene.
[229] S. Emr,et al. Retromer function in endosome-to-Golgi retrograde transport is regulated by the yeast Vps34 PtdIns 3-kinase , 2002, Journal of Cell Science.
[230] Lewis C Cantley,et al. The phosphoinositide 3-kinase pathway. , 2002, Science.
[231] H. Lehr,et al. Loss of tumor suppressor protein PTEN during renal carcinogenesis , 2002, International journal of cancer.
[232] M. Wymann,et al. Membrane transport in Caenorhabditis elegans: an essential role for VPS34 at the nuclear membrane , 2002, The EMBO journal.
[233] Alfonso Bellacosa,et al. AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[234] T. Glasz,et al. [Papillary renal cell carcinoma]. , 2001, Orvosi hetilap.
[235] M. J. Fry. Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play? , 2001, Breast Cancer Research.
[236] K. Kaestner,et al. Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .
[237] Takeshi Noda,et al. Two Distinct Vps34 Phosphatidylinositol 3–Kinase Complexes Function in Autophagy and Carboxypeptidase Y Sorting inSaccharomyces cerevisiae , 2001, The Journal of cell biology.
[238] John F. Timms,et al. Cellular function of phosphoinositide 3-kinases: Implications for development, immunity, homeostasis, and cancer , 2001 .
[239] Phillip T. Hawkins,et al. Crystal Structure and Functional Analysis of Ras Binding to Its Effector Phosphoinositide 3-Kinase γ , 2000, Cell.
[240] H. Chapuis,et al. A specific function for phosphatidylinositol 3-kinase α (p85α-p110α) in cell survival and for phosphatidylinositol 3-kinase β (p85α-p110β) in de novo DNA synthesis of human colon carcinoma cells , 2000, Oncogene.
[241] S. Emr,et al. Phosphoinositide 3-Kinases and Their FYVE Domain-containing Effectors as Regulators of Vacuolar/Lysosomal Membrane Trafficking Pathways* , 1999, The Journal of Biological Chemistry.
[242] Holger Moch,et al. The Heidelberg classification of renal cell tumours , 1997, The Journal of pathology.
[243] S. Scherer,et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.
[244] W. Linehan,et al. Chromosome imbalances in papillary renal cell carcinoma and first cytogenetic data of familial cases analyzed by comparative genomic hybridization. , 1996, Cytogenetics and cell genetics.
[245] H. Brauch,et al. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma , 1988, Nature.
[246] J. Higginson,et al. International Agency for Research on Cancer. , 1968, WHO chronicle.
[247] H. Grabstald,et al. Renal‐cell cancer , 1966, CA: a cancer journal for clinicians.
[248] M. Karno,et al. Renal cell carcinoma. , 1956, Bulletin. Tufts-New England Medical Center.